Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 4/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.37 |
| ▸ | HTR2A | P28223 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22199022 | 0.82 | HSPB1 (0.45) | HSPB1ARSLC6A4HTR2AKCNH2 | |
| SCHEMBL29570973 | 0.80 | — | — | |
| SCHEMBL157146 | 0.80 | — | — | |
| SCHEMBL328380 | 0.79 | SLC6A4 (0.50) | HSPB1ARSLC6A4HTR2AKCNH2 | |
| SCHEMBL26186321 | 0.79 | SLC6A4 (0.39) | HSPB1SLC6A4HTR2AKCNH2PPARG | |
| Fluoride SCHEMBL28080565 | 0.78 | KDM1A (0.39) | KCNH2 | |
| SCHEMBL6741205 | 0.78 | KDM1A (0.39) | KCNH2 | |
| SCHEMBL26493853 | 0.78 | ACHE (0.46) | SLC6A4KCNH2HTR1ASLC6A2 | |
| SCHEMBL22199016 | 0.77 | ACHE (0.50) | HSPB1ARMAPK14 | |
| SCHEMBL27115313 | 0.77 | ALDH1A1 (0.54) | ARSLC6A4PPARGHTR1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-10-12 | — | — | US | disclosed |
| US-20200115381-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED (CN) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115381-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND USES THEREOF IN MEDICINE | DPYD, SLC10A1, DHODH | EGFR 4439/4885KDR 3343/4885HSPB1 3552/4885 |
| US-11142527-B2 | Dihydropyrimidine compounds and uses thereof in medicine | DPYD, SLC10A1, DHODH | EGFR 4439/4885KDR 3343/4885HSPB1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.